Assessing health-related quality of life in patients with benign non-toxic goitre
Publikation: Bidrag til tidsskrift › Review › fagfællebedømt
Standard
Assessing health-related quality of life in patients with benign non-toxic goitre. / Watt, Torquil; Cramon, Per; Frendl, Daniel M.; Ware, John E.
I: Best Practice and Research: Clinical Endocrinology and Metabolism, Bind 28, Nr. 4, 08.2014, s. 559-575.Publikation: Bidrag til tidsskrift › Review › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Assessing health-related quality of life in patients with benign non-toxic goitre
AU - Watt, Torquil
AU - Cramon, Per
AU - Frendl, Daniel M.
AU - Ware, John E.
N1 - Funding Information: We would like to thank Mikel Strom, MSLIS, for helping to design and perform the literature search for this systematic review. This work was supported by the Danish Agency for Science, Technology and Innovation (grant 271-09-0143 ) and the Danish Council for Independent Research (grant 09-066886 ). L.H. is supported by an unrestricted research grant from the Novo Nordisk Foundation , and U.F.-R. from Arvid Nilsson's Fund . S.J.B. is supported by an unrestricted research grant from The Research Council at Odense University Hospital .
PY - 2014/8
Y1 - 2014/8
N2 - Health-related quality of life (HRQoL) assessments are increasingly used to evaluate treatment effects and to shape the delivery of value based care. Valid generic and disease specific tools are available for quantifying HRQoL in patients with non-toxic goitre. However, few studies have applied these validated instruments to assess HRQoL in patients with benign non-toxic goitre. Limited evidence suggests that patients with non-toxic goitre have HRQoL impairments in multiple HRQoL domains. While the HRQoL-impact of non-toxic goitre may be small relative to other severely disabling medical conditions, treatment is almost exclusively elected for HRQoL indications. Thus better quantification of HRQoL, particularly at better (or more favorable) levels where many patients score, is essential. Web and mobile technologies have eased the ability to deliver surveys to patients. Routine consideration of HRQoL provides the opportunity to monitor the impact of treatment on the outcomes most meaningful for patients and the opportunity to help shape the delivery of value based health care.
AB - Health-related quality of life (HRQoL) assessments are increasingly used to evaluate treatment effects and to shape the delivery of value based care. Valid generic and disease specific tools are available for quantifying HRQoL in patients with non-toxic goitre. However, few studies have applied these validated instruments to assess HRQoL in patients with benign non-toxic goitre. Limited evidence suggests that patients with non-toxic goitre have HRQoL impairments in multiple HRQoL domains. While the HRQoL-impact of non-toxic goitre may be small relative to other severely disabling medical conditions, treatment is almost exclusively elected for HRQoL indications. Thus better quantification of HRQoL, particularly at better (or more favorable) levels where many patients score, is essential. Web and mobile technologies have eased the ability to deliver surveys to patients. Routine consideration of HRQoL provides the opportunity to monitor the impact of treatment on the outcomes most meaningful for patients and the opportunity to help shape the delivery of value based health care.
KW - non-toxic goitre
KW - patient-reported outcome measure
KW - quality of life
UR - http://www.scopus.com/inward/record.url?scp=84904722182&partnerID=8YFLogxK
U2 - 10.1016/j.beem.2014.01.009
DO - 10.1016/j.beem.2014.01.009
M3 - Review
C2 - 25047206
AN - SCOPUS:84904722182
VL - 28
SP - 559
EP - 575
JO - Best Practice and Research in Clinical Endocrinology and Metabolism
JF - Best Practice and Research in Clinical Endocrinology and Metabolism
SN - 1521-690X
IS - 4
ER -
ID: 303679272